China Shineway(2877: HK): Beneficiary from Deregulation of Non-Essential Drug in Grassroots Level
A year ago, I wrote about China Shineway Pharmaceutical Group Ltd. (2877 HK) that has a couple of low-cost drugs that sell in the second and third...
584 Views
Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation
Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...
914 Views
CHINA HEALTHCARE - China Improving Healthcare Standards, Positive News for Pharma and Diagnostics
Quality and safety standards of drugs and medical devices will be stricter in China. CFDA may soon launch a two-track testing procedure for...
251 Views
Smartkarma: ECM Coverage Weekly Update (14 October 2017)
The Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. Buckle up! We are in...
319 Views
CSPC Pharma Placement: Visible Growth and Good Track Record
CSPC Pharma is raising USD250m today for general funding and future investment opportunities. In this insight, we will look at fundamentals of the...
265 Views